Acadia Pharmaceuticals Inc. Earnings

Acadia Pharmaceuticals Inc.’s revenue jumped 18.7% since last year same period to $244.32Mn in the Q1 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated -5.89% fall in its revenue since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit jumped 14.69% since last year same period to $18.99Mn in the Q1 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated -86.79% fall in its net profits since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit margin fell -3.38% since last year same period to 7.77% in the Q1 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated -85.96% fall in its net profit margins since last 3-months.

Acadia Pharmaceuticals Inc.’s price-to-earnings ratio after this Q1 2025 earnings stands at 15.31.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.13 - a -3.34% fall from last quarter’s estimates.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current year stand at 0.13.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Acadia Pharmaceuticals Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.